Webdisclosure.com

Search

POLYPHOR AG EQS-Adhoc: Polyphor temporarily halts enrollment in the Phase III studies of murepavadin for the treatment of patients with nosocomial pneumonia

Directive transparence : information réglementée

09/05/2019 18:00